BACKGROUND: Quinolone-resistant Neisseria gonorrhoeae (QRNG) arise from mutations in gyrA (intermediate resistance) or gyrA and parC (resistance). Here we tested the consequence of commonly isolated gyrA(91/95) and parC86 mutations on gonococcal fitness. METHODS: Mutant gyrA(91/95) and parC86 alleles were introduced into wild-type gonococci or an isogenic mutant that is resistant to macrolides due to an mtrR(-79) mutation. Wild-type and mutant bacteria were compared for growth in vitro and in competitive murine infection. RESULTS: In vitro growth was reduced with increasing numbers of mutations. Interestingly, the gyrA(91/95) mutation conferred an in vivo fitness benefit to wild-type and mtrR(-79) mutant gonococci. The gyrA(91/95), parC86 mutant, in contrast, showed a slight fitness defect in vivo, and the gyrA(91/95), parC86, mtrR(-79) mutant was markedly less fit relative to the parent strains. A ciprofloxacin-resistant (Cip(R)) mutant was selected during infection with the gyrA(91/95), parC86, mtrR(-79) mutant in which the mtrR(-79) mutation was repaired and the gyrA(91) mutation was altered. This in vivo-selected mutant grew as well as the wild-type strain in vitro. CONCLUSIONS: gyrA(91/95) mutations may contribute to the spread of QRNG. Further acquisition of a parC86 mutation abrogates this fitness advantage; however, compensatory mutations can occur that restore in vivo fitness and maintain Cip(R).
BACKGROUND:Quinolone-resistant Neisseria gonorrhoeae (QRNG) arise from mutations in gyrA (intermediate resistance) or gyrA and parC (resistance). Here we tested the consequence of commonly isolated gyrA(91/95) and parC86 mutations on gonococcal fitness. METHODS: Mutant gyrA(91/95) and parC86 alleles were introduced into wild-type gonococci or an isogenic mutant that is resistant to macrolides due to an mtrR(-79) mutation. Wild-type and mutant bacteria were compared for growth in vitro and in competitive murine infection. RESULTS: In vitro growth was reduced with increasing numbers of mutations. Interestingly, the gyrA(91/95) mutation conferred an in vivo fitness benefit to wild-type and mtrR(-79) mutant gonococci. The gyrA(91/95), parC86 mutant, in contrast, showed a slight fitness defect in vivo, and the gyrA(91/95), parC86, mtrR(-79) mutant was markedly less fit relative to the parent strains. A ciprofloxacin-resistant (Cip(R)) mutant was selected during infection with the gyrA(91/95), parC86, mtrR(-79) mutant in which the mtrR(-79) mutation was repaired and the gyrA(91) mutation was altered. This in vivo-selected mutant grew as well as the wild-type strain in vitro. CONCLUSIONS: gyrA(91/95) mutations may contribute to the spread of QRNG. Further acquisition of a parC86 mutation abrogates this fitness advantage; however, compensatory mutations can occur that restore in vivo fitness and maintain Cip(R).
Authors: B Björkholm; M Sjölund; P G Falk; O G Berg; L Engstrand; D I Andersson Journal: Proc Natl Acad Sci U S A Date: 2001-11-20 Impact factor: 11.205
Authors: J Ruiz; A Jurado; E Garcia-Méndez; F Marco; L Aguilar; M T Jiménez de Anta; J Vila Journal: J Antimicrob Chemother Date: 2001-10 Impact factor: 5.790
Authors: Nicola L Cowley; Sarah Forbes; Alejandro Amézquita; Peter McClure; Gavin J Humphreys; Andrew J McBain Journal: Appl Environ Microbiol Date: 2015-08-07 Impact factor: 4.792
Authors: Joshua Tomberg; Alena Fedarovich; Leah R Vincent; Ann E Jerse; Magnus Unemo; Christopher Davies; Robert A Nicholas Journal: Biochemistry Date: 2017-02-16 Impact factor: 3.162
Authors: Hsiao-Han Chang; Ted Cohen; Yonatan H Grad; William P Hanage; Thomas F O'Brien; Marc Lipsitch Journal: Microbiol Mol Biol Rev Date: 2015-03 Impact factor: 11.056
Authors: John Z Metcalfe; Elizabeth Streicher; Grant Theron; Rebecca E Colman; Christopher Allender; Darrin Lemmer; Rob Warren; David M Engelthaler Journal: Am J Respir Crit Care Med Date: 2017-11-01 Impact factor: 21.405
Authors: Clare L Kinnear; Twisha S Patel; Carol L Young; Vincent Marshall; Duane W Newton; Andrew F Read; Robert J Woods Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191
Authors: Joshua Tomberg; Magnus Unemo; Makoto Ohnishi; Christopher Davies; Robert A Nicholas Journal: Antimicrob Agents Chemother Date: 2013-04-15 Impact factor: 5.191